MX2019012506A - Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina. - Google Patents

Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina.

Info

Publication number
MX2019012506A
MX2019012506A MX2019012506A MX2019012506A MX2019012506A MX 2019012506 A MX2019012506 A MX 2019012506A MX 2019012506 A MX2019012506 A MX 2019012506A MX 2019012506 A MX2019012506 A MX 2019012506A MX 2019012506 A MX2019012506 A MX 2019012506A
Authority
MX
Mexico
Prior art keywords
myostatin
bind
domain proteins
stable formulations
based scaffold
Prior art date
Application number
MX2019012506A
Other languages
English (en)
Spanish (es)
Inventor
C Nashine Vishal
K Patel Rushikesh
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2019012506A publication Critical patent/MX2019012506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2019012506A 2017-05-03 2018-05-03 Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina. MX2019012506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500649P 2017-05-03 2017-05-03
PCT/US2018/030851 WO2018204617A1 (en) 2017-05-03 2018-05-03 Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin

Publications (1)

Publication Number Publication Date
MX2019012506A true MX2019012506A (es) 2019-12-19

Family

ID=62223280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012506A MX2019012506A (es) 2017-05-03 2018-05-03 Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina.

Country Status (12)

Country Link
US (2) US20200129595A1 (cg-RX-API-DMAC7.html)
EP (1) EP3618809A1 (cg-RX-API-DMAC7.html)
JP (2) JP7157082B2 (cg-RX-API-DMAC7.html)
KR (2) KR102838263B1 (cg-RX-API-DMAC7.html)
CN (1) CN110621302A (cg-RX-API-DMAC7.html)
AU (2) AU2018261154B2 (cg-RX-API-DMAC7.html)
CA (1) CA3062797A1 (cg-RX-API-DMAC7.html)
IL (2) IL270233B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019012506A (cg-RX-API-DMAC7.html)
SG (1) SG11201909709SA (cg-RX-API-DMAC7.html)
TW (1) TWI897843B (cg-RX-API-DMAC7.html)
WO (1) WO2018204617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
TWI897843B (zh) * 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
TW202432577A (zh) * 2023-02-10 2024-08-16 美商拜奧海芬治療學有限公司 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀
WO2025177263A1 (en) * 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
EP2247615B1 (en) * 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
AR071874A1 (es) * 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
WO2011051466A1 (en) * 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
PE20130041A1 (es) * 2010-02-18 2013-01-28 Bristol Myers Squibb Co Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
EP3091028A1 (en) * 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
WO2014015027A1 (en) * 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
TWI897843B (zh) * 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
US11173805B2 (en) * 2018-01-30 2021-11-16 Karma Automotive Llc State-of-charge display system

Also Published As

Publication number Publication date
JP2020518603A (ja) 2020-06-25
KR20240113600A (ko) 2024-07-22
IL270233A (cg-RX-API-DMAC7.html) 2019-12-31
WO2018204617A8 (en) 2019-01-03
AU2024204870A1 (en) 2024-08-01
IL305625B1 (en) 2024-09-01
JP2023011601A (ja) 2023-01-24
US20260069662A1 (en) 2026-03-12
JP7157082B2 (ja) 2022-10-19
CA3062797A1 (en) 2018-11-08
TWI897843B (zh) 2025-09-21
AU2018261154A1 (en) 2019-11-07
AU2018261154B2 (en) 2024-05-02
EP3618809A1 (en) 2020-03-11
KR20200003076A (ko) 2020-01-08
CN110621302A (zh) 2019-12-27
JP7442595B2 (ja) 2024-03-04
AU2024204870B2 (en) 2026-08-06
IL270233B2 (en) 2024-02-01
WO2018204617A1 (en) 2018-11-08
IL270233B1 (en) 2023-10-01
US20200129595A1 (en) 2020-04-30
IL305625A (en) 2023-11-01
TW201842929A (zh) 2018-12-16
IL305625B2 (en) 2025-01-01
KR102683806B1 (ko) 2024-07-11
SG11201909709SA (en) 2019-11-28
KR102838263B1 (ko) 2025-07-25

Similar Documents

Publication Publication Date Title
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
MX382917B (es) Formulaciones de proteínas líquidas que contienen líquidos iónicos.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
EA201890315A1 (ru) Молекулы антител, связывающие cd22
EA201691669A1 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
MX2018004022A (es) Composiciones y metodos para unir dominios extracelulares de tipo i y tipo ii como proteinas quimericas heterologas.
EA201492053A1 (ru) Белки фактора роста фибробластов 21
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
EA201592214A1 (ru) Модулятор рецептора эстрогена и его применения
WO2018204617A8 (en) STABLE FORMULATIONS OF MYOSTATIN-BOUND FIBRONECTIN SCAFFOLDING DOMAIN PROTEIN
BR112016020368A2 (pt) proteínas fc multiméricas
UY34346A (es) Proteínas de fusión para tratar trastornos metabólicos
EA201591839A1 (ru) Терапевтические пептиды
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
MX382763B (es) Proteina quimerica compuesta del dominio antagonista de factor de crecimiento nervioso secretado (ngf) y un dominio antagonista de factor alfa de necrosis tumoral (tnfa).
MX2017005467A (es) Polipéptidos de fusión de serpina y métodos para utilizar los mismos.
EA201791500A1 (ru) Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
MX2018004041A (es) Tratamiento de trastornos de acidos biliares.